This report provides the full collection of Genetic Disorders disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
Trends in Genetic Disorders partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Genetic Disorders partnering agreement structure
Genetic Disorders partnering contract documents
Top Genetic Disorders deals by value
Most active Genetic Disorders dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Genetic Disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genetic Disorders deals.
The report presents financial deal terms values for Genetic Disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Genetic Disorders dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Genetic Disorders dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Genetic Disorders deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Genetic Disorders dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Genetic Disorders deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Genetic Disorders partnering deals by specific Genetic Disorders target announced since 2014. The chapter is organized by specific Genetic Disorders therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Genetic Disorders partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Genetic Disorders partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genetic Disorders technologies and products.
Global Genetic Disorders Partnering 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Genetic Disorders trends and structure of deals entered into by leading companies worldwide.
Global Genetic Disorders Partnering 2014 to 2021 includes:
Trends in Genetic Disorders dealmaking in the biopharma industry since 2014
Access to headline, upfront, milestone and royalty data
Access to hundreds of Genetic Disorders deal contract documents
Comprehensive access to over 590 Genetic Disorders deal records
The leading Genetic Disorders deals by value since 2014
Most active Genetic Disorders dealmakers since 2014
The report includes deals for the following indications: Cystic Fibrosis (CF), Down syndrome, Fragile X Syndrome, Hereditary angioedema, Huntington's disease, Rare genetic disorders, Neurofibromatosis, Sickle cell disease, plus other genetic indications.
In Global Genetic Disorders Partnering 2014 to 2021, available deals and contracts are listed by:
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Genetic Disorders Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 590 genetic disorders deals.
Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Genetic Disorders dealmaking 2.1. Introduction 2.2. Genetic Disorders partnering over the years 2.3. Genetic Disorders partnering by deal type 2.4. Genetic Disorders partnering by industry sector 2.5. Genetic Disorders partnering by stage of development 2.6. Genetic Disorders partnering by technology type 2.7. Genetic Disorders partnering by therapeutic indication
Chapter 4 - Leading Genetic Disorders deals and dealmakers 4.1. Introduction 4.2. Most active in Genetic Disorders partnering 4.3. List of most active dealmakers in Genetic Disorders 4.4. Top Genetic Disorders deals by value
Chapter 5 - Genetic Disorders contract document directory 5.1. Introduction 5.2. Genetic Disorders partnering deals where contract document available
Chapter 6 - Genetic Disorders dealmaking by therapeutic target 6.1. Introduction 6.2. Deals by Genetic Disorders therapeutic target
4D Molecular Therapeutics
Abby Grace Foundation
Altius Institute for Biomedical Sciences
American Heart/Stroke Association
American Society of Human Genetics
ANZAC Reserach Institute
AOP Orphan Pharmaceuticals
Bambino Gesu Children's Hospital
Baylor College of Medicine
Beyond Batten Disease Foundation
Biomedical Catalyst Fund (UK)
Brigham and Women's Hospital
Buck Institute for Age Research
California Institute for Biomedical Research
California Institute for Regenerative Medicine
CANbridge Life Sciences
Cancer Prevention Pharmaceuticals
Case Western Reserve University
Castle Creek Pharmaceuticals
Center for Human Genetics and Laboratory Medicine
Centers for Disease Control and Prevention
Centre for Drug Research and Development (CDRD)
Children's Hospital Los Angeles
Children's Hospital of Philadelphia
Children's National Health System
Children's Hospital Oakland Research Institute (CHORI)
Cincinnati Children's Hospital Medical Center
Claire's Place Foundation
Clinic for Special Children
Columbia University Medical Center
Courtagen Life Sciences
Cure Sanfilippo Foundation
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation Therapeutics
Cystic Fibrosis Trust
Cystinosis Research Foundation
Dainippon Sumitomo Pharma
Dalton Pharma Services
David and Barbara Roux
de Duve Institute
Department of Health and Human Services
Department of Veterans Affairs
DMS Health Technologies
Duchenne Therapy Network
Dystrophic Epidermolysis Bullosa Research Association of America
Emmaus Life Sciences
Fertility SOURCE Companies
Flemish agency for Innovation by Science and Technology
Food and Drug Administration (FDA)
Foundation For Angelman Syndrome Therapeutics
Foundation for the Children of the Californias
Fox Chase Cancer Center
FRAXA Research Foundation
Friedreichs Ataxia Research Alliance
FSHD Global Research Foundation
Geisinger Health System
Geneva University Hospitals
Genome Institute of Singapore
George Washington University
Global Blood Therapeutics
Good Start Genetics
Grace Wilsey Foundation
Great Ormond Street Hospital (GOSH)
Hereditary Neuropathy Foundation
Icahn School of Medicine at Mount Sinai
Imperial College London
Indiana University-Purdue University Indianapolis
Indian Institute of Science Education and Research
Inova Translational Medicine Institute
Insight Centre for Data Analytics
Institute for Genome Statistics and Bioinformatics
Institute of Child Health
Institute of Human Genetics
Israeli Ministry of Industry and Commerce
Jeffrey Modell Foundation
Kings College London
La Jolla Pharmaceutical
Lead Discovery Center
Les Laboratoires Servier
Linda Crnic Institute for Down Syndrome
Louisiana State University
Lumicera Health Services
Massachusetts Eye and Ear Infirmary
Massachusetts General Hospital
Massachusetts Institute of Technology
Mauli Ola Foundation
Maxor National Pharmacy
Medical College of Wisconsin
Medical University of South Carolina
Merck and Co
Mitsubishi Tanabe Pharma
Mount Sinai Medical Center
Murdoch Childrens Research Institute
National Center for Advancing Translational Sciences (NCATS)
Lung and Blood Institute
National Human Genome Research Institute
National Institute of Allergy and Infectious Diseases
National Institute of Child Health and Human Development
National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
National Institute on Aging
National Institutes of Health
National Newspaper Publishers Association
National Organization for Rare Disorders
National Psoriasis Foundation
National Science Foundation
National Taiwan University Hospital
Nationwide Children's Hospital
New York Blood Center
New Zealand Pharmaceuticals
Orsini Healthcare Specialty Pharmacy
Paris Descartes University
Progenitor Cell Therapy
Progeria Research Foundation
Queen Mary University of London
Radboud University Nijmegen Medical Centre
Rady Children's Institute for Genomic Medicine
Rare Diseases Clinical Research Network
Rare Genomics Institute
Regeneron Genetics Center
Reproductive Medicine Associates of New York
Rett Syndrome Research Trust
RUCDR Infinite Biologics
Scripps Research Institute
Sharp Edge Labs
St. Jude Children's Research Hospital
Stanford University School of Medicine
Swedish Orphan Biovitrum
T-TOP Clinical Research
Takeda America Holdings
Tel Aviv University
Tetra Discovery Partners
Teva Pharmaceutical Industries
Texas Children's Hospital
The HUB Foundation
The Nemours/Alfred I duPont Hospital for Children
Tuberous Sclerosis Alliance (TS Alliance)
UK Cystic Fibrosis Gene Therapy Consortium
Universite catholique de Louvain
University College Dublin
University College London
University of Alabama
University of Auckland
University of Bonn
University of California Irvine
University of California Los Angeles
University of California San Francisco
University of Cambridge
University of Cincinnati
University of Colorado
University of Colorado Denver
University of Edinburgh
University of Florida
University of Massachusetts
University of Massachusetts Medical School
University of Nebraska
University of Nevada
University of North Carolina
University of Notre of Dame
University of Oxford
University of Pennsylvania
University of Pittsburgh
University of Quebec
University of South Florida
University of Texas Southwestern Medical Center
University of Toledo
University of Utah
University of Washington
University of Zambia
University of Zurich
Victorian Clinical Genetics Services
Wake Forest University
Warren Family Research Center for Drug Discovery and Development